Indications for: LOTEMAX
Steroid-responsive ocular diseases. Post-op inflammation after ocular surgery.
- Placebo-controlled clinical studies demonstrated that Lotemax is effective for the treatment of anterior chamber inflammation as measured by cell and flare.
Giant Papillary Conjunctivitis
- Placebo-controlled clinical studies demonstrated that Lotemax was effective in reducing the signs and symptoms of giant papillary conjunctivitis after 1 week of treatment and continuing for up to 6 weeks while on treatment.
Seasonal Allergic Conjunctivitis
- A placebo-controlled clinical study demonstrated that Lotemax was effective in reducing the signs and symptoms of allergic conjunctivitis during peak periods of pollen exposure.
- Controlled clinical studies of patients with uveitis demonstrated that Lotemax was less effective than prednisolone acetate 1%. Overall, 72% of patients treated with Lotemax experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with 1% prednisolone acetate. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with Lotemax and 6% with prednisolone acetate 1%.
Steroid-responsive diseases: 1–2 drops into affected eye(s) 4 times daily. May give up to 1 drop every 1hr within the 1st week of therapy. Post-op: 1–2 drops into operated eye(s) 4 times daily beginning 24hrs after surgery, continue for 2wks post-op.
Ocular fungal, viral, or mycobacterial infections.
Reevaluate if no improvement after 2 days. Prescribe initially and renew only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Contact lenses (remove during therapy and when eyes are inflamed). Pregnancy. Nursing mothers.
Local reactions (eg, blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation. May delay healing and increase bleb formation after cataract surgery; also, Oint/Gel: anterior chamber inflammation, conjunctival hyperemia, corneal edema, eye pain.
Susp—5mL, 10mL, 15mL, Oint—3.5g; Gel—5g